A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.

Inclusion Criteria:

• Non-Small Cell Lung Cancer, Stage IIIB or IV that is not amenable to either surgery of curative intent or radiation therapy
• Tumor that can be measured by x-ray or scan
• Adequate organ function

Exclusion Criteria:

• Inability to swallow capsules
• Documented brain metastases
• Prior chemotherapy or biological therapy for this disease